Oral Tirzepatide Class Action Lawsuit – Consumer Safety Alert

Chimicles Schwartz Kriner & Donaldson-Smith LLP has filed a nationwide class action lawsuit involving the marketing and sale of unapproved oral tirzepatide tablets. The lawsuit alleges that online telehealth companies and compounding pharmacies deceived consumers by promoting these tablets as safe and effective GLP-1 weight-loss medications, even though no FDA-approved oral tirzepatide exists and no clinical evidence supports the effectiveness of any oral tirzepatide, oral GLP-1/GIP pill, tirzepatide ODT, “oral tirz,” or dual agonist weight-loss tablet.

The class action lawsuit names OpenLoop Health Inc., Triad Rx Buyer LLC, and Triad Rx Inc. as defendants. It alleges that these companies—together with a network of consumer-facing telehealth brands—sold a product falsely represented as oral tirzepatide, oral GLP-1/GIP, tirzepatide ODT, or a tirzepatide alternative, despite the absence of any FDA-approved oral version of tirzepatide and despite the lack of an absorption-enhancing delivery system required for safe and effective peptide absorption.

What the Lawsuit Alleges

Tirzepatide is the active ingredient in Mounjaro® and Zepbound®, two FDA-approved injectable GLP-1/GIP medications. Because tirzepatide is a peptide, it cannot survive oral ingestion without a specialized absorption enhancer or delivery technology.

The only FDA-approved oral GLP-1 drug for weight loss, Wegovy® (oral semaglutide), uses a patented absorption enhancer called SNAC. The “oral tirzepatide,” “tirzepatide ODT,” “oral GLP-1/GIP pill,” and “oral dual agonist” tablets marketed by Defendants did not and do not contain any delivery mechanism capable of enabling oral bioavailability.

The lawsuit further alleges that Defendants:

• Marketed unapproved and unproven oral tirzepatide tablets and ODT-style dissolving tablets
• Represented these compounded products as legitimate GLP-1 weight-loss medications
• Used telehealth storefronts and shell websites to create the appearance of independent providers
• Issued prescriptions through an automated process with little or no medical review
• Dispensed the tablets through Triad Rx or Triad Rx Buyer LLC
• Misled consumers into believing the tablets were safe, effective, FDA-compliant, or equivalent to Mounjaro®, Zepbound®, or Rybelsus®

Consumers have reported that these tablets were ineffective, unsafe, improperly compounded, or distributed without any genuine medical evaluation.

Who May Be Affected

You may be part of the proposed class if you purchased oral tirzepatide, oral GLP-1 capsules, tirzepatide ODT tablets, or any similar compounded GLP-1 product from online brands or telehealth websites, including but not limited to:

MEDVi
Friday’s Health (Fridays)
Remedy Meds
Prime Health
FuturHealth
Agile Telehealth
Diddly Health
Gala GLP-1
HeyRemmy (Remmy)
MyStart Health
24HrDoc
Intimate Rose
Lovely Meds
HeyFeels (feels)

This includes any telehealth website or online clinic that sold “oral tirzepatide” and fulfilled orders through Triad Rx or Triad Rx Buyer LLC.

Potential Indicators That You May Have Been Misled

Consumers have reported experiences such as:

• Being told that “oral tirzepatide works like Rybelsus,” “oral Mounjaro,” “oral Zepbound,” “Mounjaro pill,” or “Zepbound pill.”
• Receiving tablets dispensed by Triad Rx or Triad Rx Buyer LLC
• Being prescribed the medication without ever speaking to a licensed clinician
• Experiencing no weight-loss effects

If you experienced any of these issues, you may be eligible to participate in the lawsuit.

If You Purchased Oral Tirzepatide, We Want to Hear from You

We want to hear from you if you purchased oral tirzepatide, oral GLP-1/GIP peptides, tirzepatide ODT tablets, or any other compounded oral tirzepatide GLP-1 product from an online telehealth company.